How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/naphazoline-hydrocloride-pheniramine-maleate-panthenol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Naphazoline hydrocloride + Pheniramine Maleate + Panthenol — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Naphazoline hydrocloride + Pheniramine Maleate + Panthenol (Naphazoline hydrocloride + Pheniramine Maleate + Panthenol) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sympathomimetic agent and antihistamine. Area: Ophthalmology.

phase 3 Sympathomimetic agent and antihistamine Alpha-adrenergic receptor (alpha-1 adrenergic receptor) and H1 receptor Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Naphazoline hydrocloride + Pheniramine Maleate + Panthenol (Naphazoline hydrocloride + Pheniramine Maleate + Panthenol) — EMS. Naphazoline hydrochloride is a sympathomimetic agent that acts as an alpha-adrenergic agonist, while pheniramine maleate is an antihistamine that exerts its effects by competitively inhibiting the action of histamine at the H1 receptor. Panthenol, a form of vitamin B5, has moisturizing and soothing properties.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Naphazoline hydrocloride + Pheniramine Maleate + Panthenol TARGET	Naphazoline hydrocloride + Pheniramine Maleate + Panthenol	EMS	phase 3	Sympathomimetic agent and antihistamine	Alpha-adrenergic receptor (alpha-1 adrenergic receptor) and H1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sympathomimetic agent and antihistamine class)

EMS · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Naphazoline hydrocloride + Pheniramine Maleate + Panthenol — Competitive Intelligence Brief. https://druglandscape.com/ci/naphazoline-hydrocloride-pheniramine-maleate-panthenol. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab